Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer

Inclusion Criteria: * Histologically or cytologically confirmed non-small cell lung carcinoma (NSCLC) meeting the following criteria: * The following subtypes are eligible: * Adenocarcinoma (including bronchoalveolar) * Large cell carcinoma (including giant and clear cell carcinomas) * Poorly differentiated carcinoma * No squamous cell histology * Unresectable stage II-III disease * Tumor must not invade the trachea or major arterial or venous structures * Measurable or evaluable disease * Measurable disease defined as ? 1 lesion that can be accurately measured in ? 1 dimension as ? 20 mm with conventional techniques or as ? 10 mm with spiral CT scan * No evidence of CNS disease, including primary brain tumor or brain metastases * ECOG performance status (PS) 0-1 or Karnofsky PS 60-100% * Life expectancy \> 6 months * Granulocyte count ? 1,500/mm³ * Platelet count ? 100,000/mm³ * Bilirubin \< 1.25 times upper limit of normal (ULN) * AST \< 2.5 times ULN * Creatinine normalOR creatinine clearance ? 60 mL/min * FEV\_1 ? 1.0 liters * 24-hour urine protein \< 1,000 mg (for patients with urine protein:creatinine ratio \[by urine analysis\] \> 1.0) * No hemoptysis within the past 12 months (defined as bright red blood in sputum of \> 1 teaspoon) * No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies * No history of allergic reactions attributed to carboplatin or taxane * No serious or nonhealing wound, ulcer, or bone fracture * No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days * No significant traumatic injury within the past 14 days * No clinically significant cardiovascular disease, including any of the following: * Cerebrovascular accident within the past 6 months * Uncontrolled hypertension * Myocardial infarction or unstable angina within the past 6 months * New York Heart Association class II-IV congestive heart failure * Serious cardiac arrhythmia requiring medication * Unstable angina pectoris * Clinically significant peripheral vascular disease * No known bleeding diathesis or coagulopathy * No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices) * No uncontrolled intercurrent illness including, but not limited to, the following: * Ongoing or active infection * Psychiatric illness or social situations that would limit study compliance * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for ? 6 months after completion of study treatment * No HIV positivity * No prior chemotherapy * No prior epidermal growth factor receptor-targeted therapy * No prior vascular endothelial growth factor-targeted therapy * No prior chest radiotherapy * No major surgery or open biopsy within the past 14 days * No concurrent treatment with full-dose anticoagulation * Low-dose anticoagulants (e.g., warfarin) to maintain patency of central venous catheter allowed provided all of the following criteria are met: * Daily dose of warfarin \< 1 mg * INR \< 1.5 * No other concurrent investigational agents * No concurrent major surgical procedures * No other concurrent anticancer agents or therapies * No concurrent chronic treatment with aspirin (\> 325 mg daily) or nonsteroidal anti-inflammatory agents * No dexamethasone as an antiemetic during chemoradiotherapy * No colony-stimulating factors during chemoradiotherapy